
Revolutionizing Cancer Care: Padcev and Keytruda’s Transformative Impact on Bladder Cancer
Padcev (enfortumab vedotin) and Keytruda (pembrolizumab) offer new hope as a combination therapy for metastatic urothelial carcinoma, a severe bladder cancer. The combination therapy has shown an 86% disease control rate and a 68% objective response rate, with 79% of patients maintaining